| Protocol Sort descending | Protocol Title | Status |
|---|---|---|
| HPTN 035 | Phase II/IIb Safety and Effectiveness Study of the Vaginal Microbicides BufferGel and 0.5% PRO2000/5 Gel (P) for the Prevention of HIV Infection in Women | Concluded |
| HPTN 059 | Phase II Expanded Safety and Acceptability Study of the Vaginal Microbicide 1% Tenofovir Gel | Concluded |
| HVTN 095/MTN-022 | A phase 1 clinical trial to evaluate the safety and immunogenicity of DNA/NYVAC prime boost vaccination with or without oral emtricitabine/tenofovir or vaginal tenofovir 1% gel in healthy, HIV-1–uninfected adult female participants | Withdrawn |
| MTN-001 | Phase 2 Adherence and Pharmacokinetics Study of Oral and Vaginal Preparations of Tenofovir | Concluded |
| MTN-002 | Phase I Study of the Maternal Single-Dose Pharmacokinetics and Placental Transfer of Tenofovir 1% Vaginal Gel among Healthy Term Gravidas | Concluded |
| MTN-003 | Phase 2B Safety and Effectiveness Study of Tenofovir 1% Gel, Tenofovir Disoproxil Fumarate Tablet and Emtricitabine/Tenofovir Disoproxil Fumarate Tablet for the Prevention of HIV Infection in Women | Concluded |
| MTN-003-P01 | The Wisebag Observational Pilot Study: Feasibility, Acceptability and Performance of an Electronic Event-based Monitoring System (Wisebag) | Concluded |
| MTN-003B | Bone Mineral Density Substudy Ancillary Study to MTN-003 (VOICE) | Concluded |
| MTN-003C | Household and Community Level Factors Associated with Study Product Adherence in VOICE: A Substudy of MTN-003 | Concluded |
| MTN-003C-01 | PREMIS: Preventive Misconception in HIV Prevention Trials | Withdrawn |
| MTN-003D | An Exploratory Study of Potential Sources of Efficacy Dilution in the VOICE Trial | Concluded |
| MTN-004 | Phase 1 Study of the Safety and Acceptability of 3% w/w SPL7013 Gel (VivaGel®) Applied Vaginally in Sexually Active Young Women | Concluded |
| MTN-005 | Expanded Safety and Acceptability Study of a Non-medicated Intravaginal Ring | Concluded |
| MTN-007 | A Phase 1 Randomized, Double-Blinded, Placebo-Controlled Rectal Safety and Acceptability Study of Tenofovir 1% Gel | Concluded |
| MTN-008 | Expanded Safety Investigation of Tenofovir 1% Gel in Pregnancy and Lactation | Concluded |
| MTN-009 | Prevalence of HIV-1 Drug Resistance within a Female Screening Population for HIV Prevention Trials | Concluded |
| MTN-010 | Phase 2 Expanded Safety Study of UC781 0.25% Gel Used Daily Among Sexually Active Women | Withdrawn |
| MTN-011 | Phase 1 Evaluation of Coitus on the Pharmacokinetics and Pharmacodynamics of Tenofovir 1% Gel Following Pericoital or Daily Gel Dosing | Concluded |
| MTN-012/IPM 010 | Male Tolerance Study of Dapivirine Gel Following Multiple Topical Penile Exposures | Concluded |
| MTN-013/IPM 026 | Phase 1 Safety and Pharmacokinetics of Dapivirine/Maraviroc Intravaginal Ring | Concluded |
| MTN-014 | A Phase 1 Crossover Trial Evaluating the Pharmacokinetics of Tenofovir Reduced-Glycerin 1% Gel in the Rectal and Vaginal Compartments In Women | Concluded |
| MTN-015 | An Observational Cohort Study of Women following HIV-1 Seroconversion in Microbicide Trials | Concluded |
| MTN-016 | HIV Prevention Agent Pregnancy Exposure Registry: EMBRACE Study | Concluded |
| MTN-017 | A Phase 2 Randomized Sequence Open Label Expanded Safety and Acceptability Study of Oral Emtricitabine/Tenofovir Disoproxil Fumarate Tablet and Rectally-Applied Tenofovir Reduced-Glycerin 1% Gel. | Concluded |
| MTN-018 | Committed to Having Options for Interventions to Control the Epidemic: a Follow-up Study to MTN-003 | Withdrawn |
| MTN-018B | Committed to Having Options for Interventions to Control the Epidemic: A Follow-up Study to MTN-003 - Breastfeeding Sub-study |
Withdrawn |
| MTN-018C | Committed to Having Options for Interventions to Control the Epidemic: A Follow-up Study to MTN-003 - Pregnancy Sub-study |
Withdrawn |
| MTN-019 | Phase 2 Expanded Safety Study of Tenofovir Gel in Pregnancy | Withdrawn |
| MTN-020 | A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Phase 3 Safety and Effectiveness Trial of a Vaginal Matrix Ring Containing Dapivirine for the Prevention of HIV-1 Infection in Women | Concluded |
| MTN-021 | Phase 1 Safety and Acceptability Study of 1% Tenofovir Gel in Adolescent Females | Withdrawn |
| MTN-023/IPM 030 | Phase 2a Safety Study of a Vaginal Ring Containing Dapivirine in Adolescent Females | Concluded |
| MTN-024/IPM 031 | Phase 2a Safety Study of a Vaginal Matrix Ring Containing Dapivirine in a Post-Menopausal Female Population | Concluded |
| MTN-025 | A Phase 3B Open-Label Follow-on Trial to Assess the Continued Safety of and Adherence to a Vaginal Ring Containing Dapivirine in Women | Concluded |
| MTN-026 | A Randomized, Double Blind, Placebo-Controlled, Phase 1 Safety and Pharmacokinetic Study of Dapivirine Gel (0.05%) Administered Rectally to HIV-1 Seronegative Adults | Concluded |
| MTN-027 | Phase 1 Safety and Pharmacokinetics Study of MK-2048/Vicriviroc (MK-4176)/MK 2048A Intravaginal Rings | Concluded |
| MTN-028 | Phase 1 Pharmacokinetic Trial of Two Intravaginal Rings (IVRs) Containing Different Dose Strengths of Vicriviroc (MK-4176) and MK-2048 | Concluded |
| MTN-029/IPM 039 | Phase 1 Pharmacokinetic Study of the Dapivirine Vaginal Ring in Lactating Women | Concluded |
| MTN-030/IPM 041 | A Phase 1, Randomized, Double-Blind Pharmacokinetic and Safety Study of Dapivirine/Levonorgestrel Vaginal Rings | Concluded |
| MTN-031/IPM 043 | An Open-Label Trial of the Dapivirine Vaginal Ring to Assess whether Provision of Incentives Conditional on Use Increases Product Adherence | Withdrawn |
| MTN-032 | Assessment of ASPIRE and HOPE Adherence | Concluded |
| MTN-033 | An Open Label Randomized Phase 1 Pharmacokinetic Study of Dapivirine Gel Administered Rectally to HIV-1 Seronegative Adults | Concluded |
| MTN-034 | A Phase 2a Crossover Trial Evaluating the Safety of and Adherence to a Vaginal Matrix Ring Containing Dapivirine and Oral Emtricitabine/Tenofovir Disoproxil Fumarate in an Adolescent and Young Adult Female Population | Concluded |
| MTN-035 | Acceptability, Tolerability, and Adherence of Three Rectal Microbicide Placebo Formulations among HIV Seronegative Cisgender Men, Transgender Men and Transgender Women Who Engage in Receptive Anal Intercourse | Concluded |
| MTN-036/IPM 047 | A Phase 1, Randomized Pharmacokinetics and Safety Study of Extended Duration Dapivirine Vaginal Rings | Concluded |
| MTN-037 | A Phase 1 Safety and Pharmacokinetic Study of PC-1005 (MIV-150/Zinc Acetate/Carrageenan Gel) Administered Rectally to HIV-1 Seronegative Adults | Concluded |
| MTN-038 | A Phase 1, Randomized, Pharmacokinetic and Safety Study of a 90 Day Intravaginal Ring Containing Tenofovir | Concluded |
| MTN-039 | A Phase 1 Open Label Safety and Pharmacokinetic Study of Single Dose Rectal Administration of a Tenofovir Alafenamide/Elvitegravir Insert at Two Dose Levels | Concluded |
| MTN-040 | A Double Blind Randomized Phase 2A Study of Dapivirine 0.05% gel Applied Rectally in HIV-1 Seronegative Adults | Withdrawn |
| MTN-041 | Qualitative Assessment of Acceptability of Vaginal Ring (VR) and Oral Pre-exposure Prophylaxis (PrEP) Use during Pregnancy and Breastfeeding | Concluded |
| MTN-042 | Phase 3b, Randomized, Open Label Safety Trial of Dapivirine Vaginal Ring (VR) and Oral TRUVADA Use in Pregnancy | Closed to Follow Up |
| MTN-042B | Assessing Baseline Pregnancy Outcomes in Sub-Saharan Africa | Concluded |
| MTN-043 | Phase 3B, Open-label, Safety and Drug Detection Study of Dapivirine Vaginal Ring and Oral TRUVADA® in Breastfeeding Mother-Infant Pairs | Concluded |
| MTN-044/IPM 053/CCN019 | A Randomized, Phase 1, Open-Label Study in Healthy HIV-Negative Women to Evaluate the Pharmacokinetics, Safety and Bleeding Patterns Associated with 90-Day Use of Matrix Vaginal Rings Containing 200 mg Dapivirine and 320 mg Levonorgestrel | Concluded |
| MTN-045 | Dual Purpose Prevention (DPP) Product Preferences among Couples | Concluded |
| RMP-02/MTN-006 | A two-site, Phase 1, partially-blinded, placebo-controlled safety, acceptability and pharmacokinetic trial of topical, vaginally-formulated tenofovir 1% gel applied rectally compared with oral 300 mg tenofovir disoproxil fumarate in HIV-1 seronegative adults | Concluded |
